ALVO - Alvotech
After hours:
Chart Events
MACD
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 8.17 |
| Open | 7.92 |
| Bid | 7.41 x 1000 |
| Ask | 9.30 x 1000 |
| Day's Range | 7.92 - 8.60 |
| 52 Week Range | 5.20 - 14.60 |
| Volume | |
| Avg. Volume | 84,725 |
| Market Cap | 2.221B |
| Beta (5Y Monthly) | -0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.80 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.60 |
Fair Value
Related Research
GlobeNewswireAlvotech to Participate in Jefferies Healthcare Conference
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Healthcare Conference in New York on June 7, 2023. Alvotech will present and host investor and business meetings at the conference. Anil Okay, Chief Commercial Officer is scheduled to give a presentation on June 7, 2023 at 4:30 pm EST. A webcast of the presentation will also be available and can be acc
- GlobeNewswire
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and three additional early-stage undisclosed biosimilar candidatesAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient access REYKJAVIK, Iceland and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Alvote
- GlobeNewswire
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® (golimumab) initiated, marking the fifth internally developed portfolio candidate to be dosed in a patient studySatisfactory outcome of facility reinspection remains the key requirement for U.S. approval of Biologics License Applications (BLAs) for AVT02, a proposed high-concentration,
- GlobeNewswire
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley Annual Sustainable Finance Summit on May 22, 2023. Alvotech is scheduled to hold a fireside chat on May 22, 2023 at 10:15 am ET and will host investor meetings at the conference. Alvotech is committed to the promise of biosimilars, which expand patient access to medicines globally and contribute t
- GlobeNewswire
Alvotech Issues Annual Equality Report Covering 2022
Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020Alvotech’s Equality Policy, which is based on Icelandic law, has been implemented for the workforce globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the release of its second annual Equality Report covering 2022. “Any
- GlobeNewswire
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
Polifarma will commercialize AVT06, a proposed biosimilar to Eylea® (aflibercept), in Turkey Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Polifarma Ilac San. ve tic. A.S. (“Polifarma”) for the commercialization in Turkey of AVT06, a proposed biosimilar to Eylea® (aflibercept). “It is a pleasure to join forces with Polifarma in t
- GlobeNewswire
Alvotech S.A. Annual General Meeting to be held June 6, 2023
The Annual General Meeting of Alvotech S.A. will be held on Tuesday 6 June 2023, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg. Reference is made to the attached document with regard to the final agenda. Meeting materials and all further information about the Annual General Meeting is available on the Alvotech website: https://investors.alvotech.com/corporate-governance/annual-general-meeting-2023. CONTAC
- GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
The clinical study will compare AVT05 and Simponi® in patients with moderate to severe rheumatoid arthritis REYKJAVIK, Iceland, May 04, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of Alvotech’s confirmatory patient study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The objective of the clinical study is to co
- GlobeNewswire
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2023, after U.S. markets close on Thursday, May 18, 2023. Following the release, Alvotech will conduct a business update conference call with the investment community on Friday, May 19, 2023, at 8:00 am ET (12:00 pm GMT / 14:00 pm CET). Live audio of the confere
- GlobeNewswire
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to the company’s Quality unit. Sandra Casaca has been appointed Chief Quality Officer of Alvotech and Sarah Tanksley will be joining the Board of Directors of Alvotech hf., the operating entity for Alvotech’s manufacturing site in Iceland. “I want to thank Sarah for her strong leadership and commitment to Alvotech. We are excite
- GlobeNewswire
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s reinspection of the company’s Reyk
- GlobeNewswire
Alvotech Provides Update on Corporate Sustainability Framework
REYKJAVIK, Iceland, March 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the Company’s Corporate Sustainability framework, including the release of key environmental, social and governance (“ESG”) indicators for 2022. “As part of our commitment to improve the sustainability of healthcare by providing access to more affordable
- GlobeNewswire
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara®Marketing applications for AVT04 have been submitted in major markets including U.S. and Europe REYKJAVIK, Iceland, March 17, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the presentation of two posters rel
- GlobeNewswire
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization of AVT02, a biosimilar to Humira®, in 17 countriesThree biosimilar candidates, AVT03 (Prolia®/Xgeva®), AVT06 (Eylea®) and AVT05 (Simponi®/Simponi Aria®) advanced into clinical development in 2022 Marketing applications for AVT04, a proposed biosimilar to Stelara®, were submitted in major markets in
- GlobeNewswire
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
REYKJAVIK, Iceland, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for full year 2022, after U.S. markets close on Wednesday, March 1, 2023. Following the release, Alvotech will conduct a business update conference call with the investment community on Thursday, March 2, 2023, at 8:00 am ET (13:00 pm GMT). Live
- GlobeNewswire
Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market
Alvotech (Nasdaq: ALVO) and Landsbankinn hf. have updated their market making agreement, which has been in effect since Alvotech’s shares were admitted to trading in Iceland on June 23, 2022. The updated agreement goes into effect at the start of trading on the Nasdaq Iceland market on February 15, 2023 and applies to ALVO shares trading on the Nasdaq Iceland exchange. According to the market making agreement, Landsbankinn places bids and offers on Nasdaq Iceland for ALVO shares in certain amoun
- GlobeNewswire
Settlement of Alvotech Private Share Placement Completed
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the completion of the equity transaction announced on January 23, 2023 (the “Private Share Placement”) with the transfer to the counterparties of a total of 11,834,061 treasury shares previously held by Alvotech’s subsidiary Alvotech Manco ehf. The net cash proceeds of the Private Share Placement are expected to be used for general corpo
- GlobeNewswire
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) EMA opinion on AVT04 could come as soon as the second half of 2023Reference product Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory conditions REYKJAVIK, Iceland and BAD VILBEL, Germany, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of bios
- GlobeNewswire
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand REYKJAVIK, Iceland, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23, a proposed
- GlobeNewswire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
AVT02 as Simlandi™ is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure REYKJAVIK, Iceland and DUBAI, United Arab Emirates, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC (“GHH”), the healthcare division of Yas Holding LLC, today announced that the Saudi Food & Drug Authority (“SFDA”) has approved the manufacturing and distribution of AVT02, a biosimilar for Humira
- GlobeNewswire
Alvotech Completes $137 Million Private Share Placement
REYKJAVIK, Iceland, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement of approximately $137 million, at current exchange rates, of its ordinary shares, par value $0.01 per share, (the “Shares”) at a purchase price of $11.57 per Share at current exchange rates. The Shares are expected be delivered from previously is
- GlobeNewswire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Japanese pharmaceutical company Fuji Pharma Co., Ltd. (“Fuji”, Tokyo Stock Exchange: 4554) have decided to expand their existing exclusive commercialization partnership covering Japan, by adding a new undisclosed biosimilar candidate. “We are pleased to expand our successful collaboration with Fuji. Just recently, we announced the submission of an
- GlobeNewswire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study will assess the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects. “We are delighted with the progress of the AVT05 development program,” said Joseph McClellan,
Business WireAlvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J., January 06, 2023--Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT04, Alvotech’s proposed biosimilar to Stelara® (ustekinuma
- GlobeNewswire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high-concentration of Humira® and confirmed that the data provided are sufficient to support a determination of interchangeability; approval requires satisfactory outcome of upcoming facility reinspection Alvotech is anticipating a facility reinspection by